non-small cell lung cancer (NSCLC) of clinical stages IB, II and selected stage III A
Conditions
Brief summary
Primary variable is the number of patients undergoing curatively intended surgery of non-small cell lung cancer within 43 days of initiation of study therapy.
Detailed description
Objective response rate (RECIST 1.1), Pathological response rate per ypTNM classification and per IASLC recommendations [..], R0 resection rate, Disease-free survival rate at 12 months per RECIST 1.1, Overall survival rate at 12 months, Safety and tolerability of preoperative immunotherapy, Morbidity and mortality within 90 days of curative surgery, Translational parameters [..]
Interventions
DRUGOPDIVO 10 mg/mL concentrate for solution for infusion.
Sponsors
Universitaetsklinikum Essen AöR
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary variable is the number of patients undergoing curatively intended surgery of non-small cell lung cancer within 43 days of initiation of study therapy. | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate (RECIST 1.1), Pathological response rate per ypTNM classification and per IASLC recommendations [..], R0 resection rate, Disease-free survival rate at 12 months per RECIST 1.1, Overall survival rate at 12 months, Safety and tolerability of preoperative immunotherapy, Morbidity and mortality within 90 days of curative surgery, Translational parameters [..] | — |
Countries
Belgium, Germany, Netherlands
Outcome results
None listed